Shares of Quest Diagnostics Inc. (DGX) gained 3.1% in premarket trading on Wednesday after the company said it is now offering three panel tests that can detect COVID-19 as well as other respiratory infections, like the flu. Instead of ordering separate tests, a health care provider can now use a single specimen to test for different respiratory infections, "for potentially improved patient care," Quest said. Quest is selling a Roche Holding AG's panel test that can detect flu and COVID-19, as well as two of its own panel tests that test for coronavirus infections as well as other respiratory infections. Quest's stock is up 6.4% for the year, while the S&P 500 has gained 3.2%.
-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com
(END) Dow Jones Newswires
September 30, 2020 09:12 ET (13:12 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.